On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 ...
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...
Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet ...
29 Oct - ANGERME member Yuki Hirayama recently revealed that she has been diagnosed with the rare disease called Behcet's ...
COVID-19 was significantly associated with an increased risk for alopecia areata, alopecia totalis, vitiligo, Behçet disease, Crohn disease, ulcerative colitis, rheumatoid arthritis, systemic lupus ...
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...
News Medical on MSN6d
Link between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disordersCOVID-19 survivors may develop autoimmune conditions long-term, with risks varying by severity and vaccination status, ...
AbbVie Inc. (NYSE:ABBV – Free Report) – Investment analysts at William Blair issued their Q2 2025 earnings estimates for ...
Amgen (NASDAQ:AMGN – Free Report) had its target price cut by UBS Group from $335.00 to $326.00 in a report released on Thursday, Benzinga reports. They currently have a neutral rating on the medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback